Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
暂无分享,去创建一个
E. Braunwald | G. Felker | S. Stevens | S. Dunlay | R. Tracy | B. Borlaug | M. Redfield | Omar F. AbouEzzeddine | P. McKie | Horng H. Chen | Susanna R. Stevens
[1] S. Anker,et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. , 2016, European heart journal.
[2] S. Solomon,et al. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. , 2016, Circulation. Heart failure.
[3] D. Kitzman,et al. Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction. , 2015, Journal of applied physiology.
[4] T. Lüscher. Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation. , 2015, European heart journal.
[5] Richard T. Lee,et al. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33 , 2015, Proceedings of the National Academy of Sciences.
[6] Jacob P. Kelly,et al. Patient selection in heart failure with preserved ejection fraction clinical trials. , 2015, Journal of the American College of Cardiology.
[7] A. Jaffe,et al. Soluble ST2--analytical considerations. , 2015, The American journal of cardiology.
[8] J. Januzzi,et al. The biology of ST2: the International ST2 Consensus Panel. , 2015, The American journal of cardiology.
[9] N. Houstis,et al. Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The Role of Abnormal Peripheral Oxygen Extraction , 2015, Circulation. Heart failure.
[10] Jagmeet P. Singh,et al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. , 2014, Heart rhythm.
[11] J. Mariani,et al. Determinants and implications of elevated soluble ST2 levels in heart failure. , 2014, International journal of cardiology.
[12] J. Butler,et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). , 2014, The American journal of cardiology.
[13] W. Kraus,et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. , 2014, American journal of physiology. Heart and circulatory physiology.
[14] J. Gottdiener,et al. SOLUBLE ST2 AND GALECTIN-3 ARE ASSOCIATED WITH SUBCLINICAL DIASTOLIC DYSFUNCTION IN OLDER ADULTS , 2014 .
[15] J. Cohn,et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial , 2014, Circulation. Heart failure.
[16] R. D. de Boer,et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. , 2014, Clinical chemistry.
[17] D. Levy,et al. Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening , 2013, Journal of the American Heart Association.
[18] D. Christiani,et al. Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome , 2013, Critical care medicine.
[19] W. Kraus,et al. Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes , 2013, Circulation. Heart failure.
[20] Naoki Sato,et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. , 2013, International journal of cardiology.
[21] S. Kritchevsky,et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[22] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[23] G. Maurer,et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature , 2013, Journal of molecular and cellular cardiology.
[24] J. Wojta,et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue , 2013, International Journal of Obesity.
[25] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[26] C. Ayers,et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. , 2013, Clinical chemistry.
[27] R. Vasan,et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. , 2012, Clinical chemistry.
[28] E. Braunwald,et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. , 2012, Circulation. Heart failure.
[29] J. McMurray,et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology , 2012, European journal of heart failure.
[30] J. Lupón,et al. Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure , 2012, European journal of heart failure.
[31] Richard T. Lee,et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. , 2012, Clinical chemistry.
[32] S. Manzano-Fernández,et al. Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.
[33] W. Kop,et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. , 2011, Clinical chemistry.
[34] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[35] S. Manzano-Fernández,et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. , 2011, The American journal of cardiology.
[36] E. Tham,et al. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. , 2010, The international journal of biochemistry & cell biology.
[37] P. Clopton,et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients. , 2010, American heart journal.
[38] T. Mueller,et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[39] M. Picard,et al. Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea , 2009, Circulation. Heart failure.
[40] O. Muller,et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. , 2008, Journal of the American College of Cardiology.
[41] R. Fitzgerald,et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. , 2008, Journal of cardiac failure.
[42] S. Réhman,et al. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. , 2008, Journal of the American College of Cardiology.
[43] Richard T. Lee,et al. The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.
[44] Ashley M. Miller,et al. IL-33 reduces the development of atherosclerosis , 2008, The Journal of experimental medicine.
[45] D. Lloyd‐Jones,et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.
[46] Richard T. Lee,et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.
[47] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[48] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[49] Richard T. Lee,et al. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.
[50] Paulus Wj. Cytokines and heart failure. , 2000 .
[51] W. Paulus. Cytokines and heart failure. , 2000, Heart failure monitor.
[52] M. Busslinger,et al. Alternative promoter usage of the Fos‐responsive gene Fit‐1 generates mRNA isoforms coding for either secreted or membrane‐bound proteins related to the IL‐1 receptor. , 1994, The EMBO journal.